![]() | ![]() |
Formats:
|
||||||||||||||||||
Gapex-5, a Rab31 Guanine Nucleotide Exchange Factor that Regulates Glut4 Trafficking in Adipocytes 1 Life Sciences Institute 2 Departments of Internal Medicine and Molecular and Integrative Physiology 3 Cellular and Molecular Biology Program University of Michigan Ann Arbor, MI 48109 4 Department of Pharmacological Sciences Stony Brook University Stony Brook, NY 11794 *Corresponding author: Alan R. Saltiel Life Sciences Institute University of Michigan 210 Washtenaw Ave. Ann Arbor, MI 48109 Email: saltiel/at/lsi.umich.edu The publisher's final edited version of this article is available at Cell Metab. See other articles in PMC that cite the published article.Summary Insulin stimulates glucose uptake by promoting translocation of the Glut4 glucose transporter from intracellular storage compartments to the plasma membrane. In the absence of insulin, Glut4 is retained intracellularly, although the mechanism underlying this process remains uncertain. Using the TC10-interacting protein CIP4 as bait in a yeast two-hybrid screen, we cloned a RasGAP and VPS9 domain-containing protein, Gapex-5/RME-6. The VPS9 domain is a guanine nucleotide exchange factor for Rab31, a Rab5 subfamily GTPase implicated in trans-Golgi Network (TGN)-to-endosome trafficking. Overexpression of Rab31 blocks insulin-stimulated Glut4 translocation, whereas knockdown of Rab31 potentiates insulin-stimulated Glut4 translocation and glucose uptake. Gapex-5 is predominantly cytosolic in untreated cells; its overexpression promotes intracellular retention of Glut4 in adipocytes. Insulin recruits the CIP4/Gapex-5 complex to the plasma membrane, thus reducing Rab31 activity and permitting Glut4 vesicles to translocate to the cell surface, where Glut4 docks and fuses to transport glucose into the cell. Introduction Insulin stimulates glucose transport into striated muscle and adipocytes by increasing the concentration of the facilitative glucose transporter Glut4 at the plasma membrane (Bryant et al., 2002; Saltiel and Kahn, 2001). In the absence of insulin, or following inactivation of its receptor, Glut4 undergoes endocytosis (Corvera et al., 1994; Garippa et al., 1996). Approximately half of intracellular Glut4 resides in general endocytotic compartments that contain the transferrin receptor, while the other half is found in a specialized Glut4 storage compartment which lacks endocytotic markers (Martin et al., 1996; Zeigerer et al., 2002), but contains markers of the trans-Golgi network (TGN), such as AP-1 and Syntaxins 6 and 16 (Gillingham et al., 1999; Martin et al., 2000; Shewan et al., 2003). Recent studies suggest that the two pools of Glut4 are in equilibrium with each other through a continuous cycle of budding and fusion that promotes intracellular retention of the transporter (Karylowski et al., 2004). Insulin permits escape from this futile cycle, thereby stimulating exocytosis of Glut4 vesicles to the cell surface. The Rab family of small G-proteins plays an essential role in various cellular trafficking processes (Stenmark and Olkkonen, 2001), including the trafficking of Glut4 vesicles (Dugani and Klip, 2005). Rab proteins cycle between an inactive (GDP-bound) and an active (GTP-bound) state, regulated by GTPase activating proteins (GAPs) that promote GTP hydrolysis and guanine nucleotide exchange factors (GEFs) that promote exchange of GDP for GTP. The critical role of Rab proteins in vesicle trafficking suggests that they may represent a site of integration for signals from the insulin receptor. The stimulation of glucose transport by insulin in adipocytes is thought to require two distinct signaling pathways. Upon activation, the insulin receptor catalyzes the tyrosine phosphorylation of the IRS family of adaptor proteins, which results in recruitment and activation of phosphatidylinositol 3-kinase (PI3K), and downstream activation of PIP3-dependent processes (Kelly and Ruderman, 1993; Kelly et al., 1992). Although this pathway is required for Glut4 translocation, substantial evidence suggests that it is not sufficient (reviewed in Saltiel and Pessin, 2002). The insulin receptor also catalyzes the tyrosine phosphorylation of the adapter protein APS (Liu et al., 2002), resulting in the recruitment and tyrosine phosphorylation of c-Cbl or Cbl-b (Liu et al., 2003), and the subsequent activation of the Rho family GTPase TC10 (Chiang et al., 2001). The absolute requirement for this pathway is uncertain. Expression of dominant negative mutants of most of these proteins block glucose transport (Baumann et al., 2000; Chiang et al., 2001; Liu et al., 2003; Liu et al., 2002), while knockdown of CAP, Cbl and APS have led to inconsistent effects (Ahn et al., 2004; Mitra et al., 2004). In this regard, we have recently shown that upon lowering Glut1 levels, knock down of CAP (Chiang et al, in preparation) or TC10 (Chang et al., 2006) blocks insulin-stimulated glucose uptake and Glut4 translocation. Once activated, TC10 recruits a number of effectors that participate in insulin-stimulated Glut4 trafficking, docking and fusion, including the exocyst protein Exo70 (Inoue et al., 2003) and the multifunctional adaptor protein CIP4 (Cdc42 interacting protein 4) (Chang et al., 2002). CIP4 interacts with the active, GTP-loaded forms of Cdc42 (Aspenstrom, 1997) and TC10 (Chang et al., 2002). The N-terminal FCH domain of CIP4 resembles the non-kinase domain of the FER and Fes/Fps family of tyrosine kinases and contains a BAR domain (Itoh et al., 2005). CIP4 also harbors two central coiled-coil motifs and a C-terminal SH3 domain (Aspenstrom, 1997). We previously reported that overexpressed CIP4 is predominantly found in an intracellular compartment in adipocytes under basal conditions, and is recruited to the plasma membrane following insulin stimulation (Chang et al., 2002). TC10 activation is both necessary and sufficient for this translocation of CIP4. The FCH domain, which has been shown to interact with microtubules (Tian et al., 2000), is necessary for translocation to the plasma membrane (Chang et al., 2002), suggesting that movement of CIP4 might proceed along a microtubule tract. Overexpression of mutant forms of CIP4 that cannot translocate to the plasma membrane or interact with TC10 block insulin-stimulated Glut4 translocation. In contrast, a mutant of CIP4 lacking the SH3 domain is constitutively localized to the plasma membrane and has no effect on Glut4 translocation (Chang et al., 2002). These data suggest that CIP4 is an adaptor protein that recruits additional molecules to the plasma membrane, some of which may participate in the regulation of Glut4 trafficking in response to insulin. To better understand the role of CIP4 in insulin-stimulated Glut4 translocation, we screened for CIP4-interacting proteins using the yeast-two hybrid assay system. Here we describe one such binding partner, Gapex-5, an evolutionarily conserved multi-domain protein that activates Rab31, a Rab5 subfamily GTPase that influences the trafficking of Glut4 vesicles in adipocytes. Results Identification and expression of mouse Gapex-5 To better understand its role in the regulation of insulin-stimulated glucose uptake, we used CIP4 as bait to screen a yeast two-hybrid cDNA library derived from 3T3-L1 adipocytes. A 1.6 kb fragment was identified encoding a novel protein lacking the N- and C-termini. The full-length sequence was assembled by using the sequence of the yeast two-hybrid fragment to search for overlapping ESTs in the NCBI database. A 4.3 kb full-length cDNA was cloned by RT-PCR using total RNA from 3T3-L1 adipocytes. The reading frame started with an ATG codon in a Kozak consensus sequence and encoded a protein of 1437 amino acids (Figure S1). Sequence analysis using the NCBI database revealed that protein encoded by this cDNA is evolutionarily conserved, and contains an N-terminal Ras GTPase activating protein (GAP) domain, a C-terminal VPS9 domain (containing a Rab5 guanyl nucleotide exchange factor), and a central PXXP sequence similar to other SH3 domain-binding sequences (Figure 1A
To examine the tissue distribution of Gapex-5, we performed multi-tissue Northern blot analysis using mouse total RNA from various tissues with the 1.6 kb yeast-two hybrid prey as the probe. As shown in Figure 1B Interaction of Gapex-5 with CIP4 A series of truncation mutants were generated to evaluate the interaction of Gapex-5 with CIP4 (Figure 2A
The interaction between Gapex-5 and CIP4 was further examined by co-immunoprecipitation. Myc-tagged wild-type CIP4 or various mutants were overexpressed either alone or in combination with HA-Gapex-5 in Cos-1 cells as indicated in Figure 2C CIP4 recruits Gapex-5 to the plasma membrane in response to insulin We reported previously that exogenously expressed CIP4 translocates to the plasma membrane of adipocytes in response to insulin stimulation (Chang et al., 2002). We sought to confirm these results with endogenous CIP4 in adipocytes by immunofluorescence using a monoclonal antibody against CIP4. In the absence of insulin, endogenous CIP4 displayed punctate intracellular staining, as well as some plasma membrane localization. Insulin stimulated the accumulation of endogenous CIP4 at the cell surface in a manner similar to the expressed protein (Figure 2D To determine whether CIP4 affects the localization of Gapex-5, we overexpressed myctagged CIP4 and HA-tagged Gapex-5 in adipocytes and examined their localization by confocal microscopy and quantified the amount of Gapex-5 present at the plasma membrane (Figure 2E and 2F To determine whether TC10 activation is required for the recruitment of the CIP4/Gapex-5 complex to the plasma membrane, we transfected adipocytes with myc-Gapex-5 and eGFP-CIP4, together with HA-tagged wild-type or constitutively active (Q75L) TC10 or empty vector. After 24 hr, the cells were immunostained and analyzed by confocal microscopy. The CIP4/Gapex-5 complex only translocated to the plasma when TC10 (Q75L) was co-expressed, indicating that TC10 activation is sufficient for CIP4/Gapex-5 translocation (Figure S2). The VPS9 domain of Gapex-5 interacts with GDP-bound Rab5 and Rab31 The VPS9 domain, together with an upstream tandem helical bundle (HB) region, is a specific GDP/GTP exchange module for the Rab5 subfamily of G proteins (Carney et al., 2006; Delprato et al., 2004), which includes Rab5, Rab21, Rab22a and Rab31 (also known as Rab22b) (Stenmark and Olkkonen, 2001). The HB-VSP9 tandem of Gapex-5 is homologous to the corresponding regions of known activators of Rab5 (Figure 3A
Gapex-5 is a GEF for Rab31 Although Rab31 is a Rab5 family member, there is little information about downstream effectors, and we thus sought to identify Rab31 binding proteins. We incubated a GST-Rab31 fusion protein with GDP or GTPγS, followed by addition of lysates from Cos-1 cells. Precipitated proteins were separated by SDS-PAGE and stained with Coomassie blue. A 180 kDa protein was identified that preferentially interacted with GTPγS-bound Rab31 (data not shown). To determine if this protein corresponds to the Rab5 effector EEA1 (early endosome antigen 1) (Simonsen et al., 1998), we immunoblotted the precipitated proteins with antibodies against EEA1, and found that endogenous EEA1 is the 180kDa Rab31-binding protein (Figure 3C To determine whether Gapex-5 is required for GTP loading on Rab31 in vivo, we knocked down Gapex-5 in HEK-293 cells, and assayed Rab31 activity by pull-down with EEA1. Knockdown of Gapex-5 with siRNA oligo reduced the activation state of Rab31 by almost 60% (Figure 3E and 3F Gapex-5 overexpression blocks the insulin-stimulated Glut4 translocation Because Gapex-5 is constitutively associated with CIP4, a protein previously implicated in regulating insulin-stimulated Glut4 translocation (Chang et al., 2002), we overexpressed full-length Gapex-5 and its deletion mutants to examine their role in the regulation of Glut4 translocation (Figure 4
Overexpression of Gapex-5 could potentially inhibit the plasma membrane localization of Glut4 by blocking the insulin-stimulated exocytosis of Glut4, or accelerating its internalization from the cell surface. To distinguish between these possibilities, we used a Glut4 mutant that cannot efficiently undergo endocytosis from the plasma membrane. Mutations in the N-terminal F5QQI8 motif of Glut4, particularly substitution of phenylalanine to alanine (F5A), results in accumulation of Glut4 at the plasma membrane due to a decreased rate of endocytosis (Garippa et al., 1994; Piper et al., 1993). Interestingly, Gapex-5 overexpression inhibited both basal and insulin-stimulated plasma membrane localization of the F5A mutant (Figure 4D Although the precise mechanism by which Glut4 is internalized from the cell surface is not clear, it is thought that Glut4 undergoes endocytosis through clathrin-coated pits in a manner similar to the transferrin receptor (Robinson et al., 1992; Slot et al., 1991). Overexpression of Gapex-5 did not affect the uptake of Texas Red-conjugated transferrin in 3T3-L1 adipocytes (data not shown). To determine directly whether Gapex-5 can regulate endocytosis of Glut4 from the cell surface, we transfected adipocytes with a Glut4 construct possessing an exofacial myc epitope tag inserted between transmembrane domains 1 and 2 (Kanzaki et al., 2001), and determined the percentage of cells with plasma membrane and/or intracellular staining of myc. Interestingly, Gapex-5 overexpression did not increase the number of cells with intracellular myc label (Figure S3). These data, combined with the effect of Gapex-5 on endocytosis-defective Glut4, indicate that Gapex-5 probably does not substantially influence at least the initial endocytosis of Glut4. However, it is conceivable that Gapex-5 could play a role in subsequent endocytotic steps, perhaps including fusion of clathrin-coated vesicles with early endosomes. Plasma membrane targeting of Gapex-5 relieves the inhibition of Glut4 translocation Overexpressed Gapex-5 is predominantly intracellular in the basal state and is recruited to the cell surface by CIP4 in response to insulin stimulation (Figure 2
To target Gapex-5 to the plasma membrane by an independent method, we also generated a chimera of Gapex-5 linked to the C-terminal region of H-Ras (Figure 5C Overexpression of Rab31 blocks Glut4 translocation in adipocytes Although previous studies have shown that Rab31 colocalizes with markers of trans-Golgi, TGN and endosomes (Field et al., 2000; Rodriguez-Gabin et al., 2001), its localization in adipocytes has not been described. We thus sought to examine the immunolocalization of HA-Rab31 in adipocytes. Interestingly, the overexpressed Rab31 protein was concentrated in a perinuclear compartment, where it partially colocalized with endogenous EEA1 and syntaxin-6 (Figure S4), markers for early endosomes and TGN, respectively. Because Gapex-5 is a regulator of Rab31, we reasoned that it might maintain intracellular Rab31 in an active state, and thus tested the effect of overexpression of Rab31 and its mutants on Glut4 translocation (Figure 6A
Rab31 knockdown potentiates insulin-stimulated Glut4 translocation and glucose uptake To determine the effect of endogenous Rab31 on Glut4 translocation and glucose uptake, we preformed siRNA-mediated knockdowns in 3T3-L1 adipocytes. The depletion of Rab31 had no effect on the expression levels of Glut4 and caveolin, nor did it block insulin-stimulated phosphorylation of Akt or Cbl (Figure 6C To confirm that the enhanced glucose transport in the face of Rab31 knockdown is due to increased Glut4 translocation, we used adipocytes stably infected with retrovirus expressing exofacial myc-tagged Glut4-eGFP (Bogan et al., 2001). Knockdown of Rab31 in these cells significantly increased Glut4 translocation stimulated by 1 nM insulin. However, as determined by anti-myc staining in unpermeabilized cells, Glut4 did not efficiently fuse with the plasma membrane in every cell at this low dose of insulin (Figure 6E Insulin inhibits the activity of Rab31 in adipocytes We next investigated whether insulin regulates the activity of Rab31 in adipocytes. Adipocytes were treated with insulin for 0, 5, 10 or 20 min and the activation state of Rab31 was determined by pull down with GST-EEA1. Insulin reduced the GTP-dependent interaction of Rab31 with EEA1 in a time-dependent manner, suggesting that insulin inactivates Rab31 (Figure 7A and 7B
Discussion Our previous attempts to understand the contribution of TC10 to the regulation of glucose transport led us to the protein CIP4, a multi-domain adapter that is recruited to the plasma membrane in response to insulin. While overexpression of wild-type CIP4 or a mutant that is constitutively localized to the plasma membrane had no effect, overexpression of CIP4 mutants that fail to translocate to the plasma membrane blocked insulin-stimulated recruitment of Glut4 to the cell surface in adipocytes (Chang et al., 2002). These data suggested that CIP4 may act as an adaptor that recruits additional molecules to the plasma membrane to regulate Glut4 trafficking. Gapex-5 appears to be one such protein. This molecule interacts constitutively with CIP4, is predominantly intracellular, and is recruited to the plasma membrane with CIP4 in response to insulin. Whereas overexpression of Gapex-5 suppresses cell surface localization of Glut4, plasma membrane targeting of Gapex-5 by co-expression of CIP4 or introduction of a plasma membrane targeting sequence relieves the inhibitory effect of Gapex-5 on Glut4 translocation. Together, these data suggest that the intracellular localization of Gapex-5 defines its inhibitory effect on Glut4 trafficking, which is subsequently alleviated by its plasma membrane recruitment in response to insulin. Gapex-5 is present in organisms as evolutionarily divergent as worms and humans, suggesting that it has a conserved role in protein trafficking. In addition, worms deficient for rme-6, the C. elegans homolog of Gapex-5, have diminished Rab5 activation and a defect in endocytosis of the yolk receptor, YP170, from the plasma membrane (Sato et al., 2005). Interestingly, unlike the mammalian homologs, Gapex-5 from lower organisms lacks the proline-rich region required for interaction with CIP4. This suggests that in these species, the subcellular localization of Gapex-5 may not be under the same regulatory control, and that the ability to interact with CIP4 was acquired later in evolution. VPS9 domain-containing proteins catalyze the GDP/GTP exchange reaction on Rab5 family members (Carney et al., 2006; Delprato et al., 2004), which includes Rab5, Rab21, Rab22a and Rab31 (Stenmark and Olkkonen, 2001). Several GEFs for Rab5 subfamily members have been identified, including Rabex-5 (Horiuchi et al., 1997), Rin1 (Tall et al., 2001) and Alsin (Topp et al., 2004). Gapex-5 appears to be an efficient and specific activator of Rab31. This small GTP-binding protein is 45% identical to Rab5 and 71% identical to Rab22a. Like Rab5 and Rab22a (Kauppi et al., 2002; Simonsen et al., 1998), Rab31 interacts in a nucleotide-dependent manner with EEA1, a multi-domain tethering factor involved in the fusion of endosomes (Simonsen et al., 1998). However, unlike Rab22a, which interact with only the N-terminal Rab binding domain of EEA1 (Kauppi et al., 2002), Rab31 interacts with both the N- and the C-terminal Rab binding domains of EEA1, resulting in higher affinity binding. While Rab31 can associate with EEA1-containing endosomes (Figure S4), overexpression of constitutively active Rab31 does not result in the formation of large hollow endocytotic structures typically observed with the overexpression of constitutively active Rab5 (Stenmark et al., 1994). This suggests that while Rab5 can regulate homotypic endosome fusion (Stenmark et al., 1994), Rab31 probably primarily regulates heterotypic endosome fusion. Although Rab31 is poorly characterized, it is thought to play a role in TGN-to-endosome trafficking. For example, Rab31 colocalizes with markers of trans-Golgi, TGN and endosomes (Field et al., 2000; Rodriguez-Gabin et al., 2001). Furthermore, analysis of live cells using time lapse video microscopy showed that trafficking of vesicles from the TGN to endosomes occurs along microtubule tracks via small tubulo-vesicular organelles that contain Rab31 (Rodriguez-Gabin et al., 2001). The Rab31 effector EEA1 may play an essential role in the fusion of TGN-derived vesicles with endosomes. Whereas EEA1 is primarily associated with homotypic fusion of early endosomes (Mills et al., 1998), a pool of EEA1 may also be involved in fusion of post-Golgi vesicles with endosomes, through a direct interaction of EEA1 with syntaxin-6 (Simonsen et al., 1999), a t-SNARE in the TGN for vesicles arriving from the endosomal system (Mallard et al., 1998). Intracellular Glut4 is stored in a general endosomal compartment, as well as in a specialized Glut4 storage compartment (GSC), which may be derived from the TGN (Martin et al., 1996; Shewan et al., 2003 ; Watson et al., 2004; Zeigerer et al., 2002). Recent studies suggest that under basal conditions, Glut4 undergoes a futile intracellular cycle between these two compartments (Bryant et al., 2002). By preventing its trafficking to the plasma membrane, this intracellular cycling of Glut4 may be a critical element in the basal retention of Glut4. Indeed, in the absence of insulin, the Glut4 vesicles are excluded from the cell surface by a continuous cycle of budding and fusion with endosomes (Karylowski et al., 2004). This type of intracellular cycling is not unique to Glut4. For example, the yeast protein chitin synthase III (Chs3p) is also retained intracellularly by continuously cycling between the TGN and early endosomes (Valdivia et al., 2002). Furthermore, the aquaporin-2 water channel may also be retained by undergoing an intracellular cycle in a manner similar to Glut4 (Brown, 2003). Thus, it is possible that for proteins that undergo regulated transport to the plasma membrane, a continuous cycle of budding and fusion of vesicles with endosomes may be a general mechanism to promote intracellular retention of these proteins under conditions in which they are not needed at the plasma membrane. However, it should be noted that for Glut4, additional mechanisms involving a physical tether have also been proposed (Bogan et al., 2003). TC10 is an insulin-regulated GTPase that recruits multiple effectors that influence various aspects of the Glut4 vesicle trafficking. Besides regulating tethering of Glut4 vesicles at the plasma membrane by recruiting the exocyst complex (Inoue et al., 2003; Inoue et al., 2006), TC10 may also regulate intracellular retention of Glut4 vesicles by recruiting CIP4 to the plasma membrane. Our data suggest that the intracellular retention of Glut4 is controlled by Rab31 and its regulator, Gapex-5. Consistent with the effect of overexpressing Gapex-5, overexpression of the active form of Rab31 blocks translocation of Glut4. However, while the dominant negative Rab31 increases basal Glut4 translocation, overexpression of a Gapex-5 mutant lacking the Rab31 GEF domain (Gapex-5ΔHB–VPS9) does not affect basal Glut4 trafficking. This probably reflects the fact that this mutant of Gapex-5 does not act as a dominant negative inhibitor of Rab31. It would be desirable to have a point mutant of Gapex-5 that lacks GEF activity, but can still interact with Rab31. No such mutant has been identified. In contrast to the inhibitory effect of overexpressing constitutively active Rab31, the knockdown of Rab31 potentiates insulin-stimulated Glut4 translocation and glucose uptake. Previous studies have shown that Rab31 has high constitutive levels of bound GTP (Bao et al., 2002; Field et al., 2000). Here, we demonstrate that insulin decreases the GTP levels on Rab31. Thus, we propose a model (Figure 7C Experimental procedures Antibodies The anti-HA, anti-myc and anti-CblΔantibodies were purchased from Santa Cruz Biotechnology. The anti-FLAG M2 antibody was purchased from Sigma. The anti-Gapex-5 polyclonal antibody was raised against the amino-terminal residues 1–17 and was purified using protein ImmunoPure (A) IgG purification kit (Pierce). Polyclonal antibody against Caveolin and monoclonal antibodies against CIP4, EEA1, Syntaxin-6 and Rabaptin-5 were purchased from BD Biosciences and a monoclonal antibody against Rab31 was from Abnova. Phospo-Akt (ser 473) antibody was from Cell Signaling Technology. Anti-Phosphotyrosine 4G10 antibody was from Upstate Cell Signaling Solutions. Expression Constructs To create mammalian expression constructs of Gapex-5, the internal EcoRI site was destroyed by a silent mutation. The gene was now cloned into XhoI and EcoRI sites of a modified pKH3 (HA-tag) vector or pRK5myc (myc tag) vector. Myc-tagged CIP4 mutants have been previously described (Chang et al., 2002). GFP-tagged CIP4 mutants were made by subcloning into pEGFP-C1 vector. Myc-Rab22a and GST-EEA1/NT were provided by Philip Stahl (Washington University, St. Louis). Rab31 cDNA was from Francis Barr (Max Planck Institute of Biochemistry, Martinsried, Germany), and the cDNA for Rab5a was obtained from the UMR cDNA Resource Center (cdna.org). Both of these Rabs were subcloned into pKH3 or pGEX 4T-1 plasmids. Point mutants of Rab31 were created using the QuikChange method (Stratagene). The C-terminal Rab binding domain of EEA1 (residues 1245–1411) was cloned from the 3T3-L1 cDNA library by PCR and subcloned into pGEX 4T-1. The VPS9 domain and the tandem helical bundle domain of Gapex-5 (residues 1111–1437) were cloned into pGEX 4T-1. Myc-Glut1-GFP construct was from Brent Reed (Louisiana State University, Shreveport, LA). All constructs were sequenced to confirm reading frame. Cloning of Gapex-5 To search for CIP4-interacting protein, a yeast two-hybrid cDNA library derived from 3T3-L1 adipocytes was screened essentially as described (Chang et al., 2002). The Gapex-5 yeast two-hybrid hit consisted of base pairs 1311–2916. The sequence of the cDNA fragment isolated in the yeast two-hybrid screen was used to search the NCBI database for overlapping ESTs. Alignment of the ESTs indicated a full-length sequence containing Kozak consensus box and a stop codon. The entire open reading frame was cloned by RT-PCR using total RNA from 3T3-L1 adipocytes. Cell culture and electroporation of 3T3-L1 adipocytes The 3T3-L1 fibroblasts were grown in DMEM containing 10% fetal bovine serum (FBS) and differentiated into adipocytes as previously described (Baumann et al., 2000). The adipocytes were transfected with Stealth™ siRNA duplexes (Invitrogen) by electroporation as previously described (Inoue et al., 2006). Immunofluorescence Microscopy To detect myc-tagged CIP4 or Gapex-5, the cells were stained with anti-myc polyclonal antibody (Santa Cruz Biotechnology) at 2 μg/ml. To detect HA-Gapex-5 or HA-Rab31, the cells were stained with anti-hemagglutinin (HA) mAb at 2 μg/ml. After incubation with primary antibodies, cells were incubated with Alexa488 or Alexa594 goat anti-mouse or anti-rabbit IgG at 2 μg/ml (Invitrogen). Coverslips were mounted in Vectashield mounting media (Vector Laboratories). Images were captured by using an Olympus FluoView 500 laser scanning confocal microscope. In vitro GST pull-down assays GST fusion proteins were expressed in BL21(DE3)pLysS Escherichia coli strain and purified as described (Smith and Johnson, 1988). GST pull-down assays were performed as previously described (Chang et al, 2002). Nucleotide loading of GTPases To nucleotide load Rab proteins overexpressed in Cos-1 cells, the cells were lysed using a buffer containing 20 mM Hepes [pH 7.5], 150 mM NaCl, 5 mM EDTA, 5% glycerol and 1% NP-40. The lysates were combined with an equal volume of the same buffer lacking NP-40 and incubated with 1 mM GTPγS or 2 mM GDP at 30°C for 30 min. The reaction was stopped by adding 60 mM MgCl2. GST-tagged Rab proteins were similarly loaded with nucleotides using the lysis buffer containing 0.5% NP-40. 2-Deoxyglucose uptake assay The RNAi-transfected cells were re-seeded on 12-well plates and cultured for 3 days. The uptake of 2-deoxyglucose was measured as previously described (Inoue et al., 2006). Establishment of adipocytes stably expressing myc-Glut4-eGFP 3T3-L1 fibroblasts were infected with retroviral particles containing myc-Glut4-eGFP (Bogan et al., 2001), and myc-Glut4-eGFP expressing cells were sorted by FACS based on the FITC intensity. Cells with high expression levels of Glut4-eGFP were collected and differentiated into adipocytes. Rab31 activation assay To determine the effect of insulin on the activation state of Rab31, 3T3-L1 adipocytes were serum starved for 3 hr and then stimulated with or without insulin and lysed using Rab31 activation assay lysis buffer (20 mM Hepes [pH 7.5], 100 mM NaCl, 1 mM DTT, 5 mM MgCl2, 5% glycerol and 1% Triton-X-100), supplemented with protease inhibitor cocktail (Complete Mini, EDTA-free) from Roche. Lysates were diluted with an equal volume of the lysis buffer lacking Triton-X-100 and incubated with 15 μg of GST-EEAI/NT at 4°C rocking. After 1 hr, the beads were washed 4 times using the lysis buffer (containing Triton-X-100). The pull-downs and lysates were subjected to electrophoresis and analyzed by immunoblotting using an anti-Rab31 antibody. Accession numbers The sequence of mouse Gapex-5 has been deposited into GenBank under accession no. EF155419. 01 Click here to view.(653K, pdf) Acknowledgments We thank members of the Saltiel lab for critical reading of the manuscript and helpful discussions. We acknowledge Dr. Mei Zhang for expert technical assistance in cloning the full-length Gapex-5. We also acknowledge the technical assistance of Emily Lampe. This work utilized the Morphology and Image Analysis Core of the Michigan Diabetes Research and Training Center funded by NIH5P60-DK20572 from the National Institute of Diabetes & Digestive & Kidney Diseases. This work was supported by NIH grants RO1-DK061618 to ARS and DK59291 to JEP. References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||
Nat Rev Mol Cell Biol. 2002 Apr; 3(4):267-77.
[Nat Rev Mol Cell Biol. 2002]Nature. 2001 Dec 13; 414(6865):799-806.
[Nature. 2001]J Cell Biol. 1994 Aug; 126(4):979-89.
[J Cell Biol. 1994]J Biol Chem. 1996 Aug 23; 271(34):20660-8.
[J Biol Chem. 1996]J Cell Biol. 1996 Aug; 134(3):625-35.
[J Cell Biol. 1996]Genome Biol. 2001; 2(5):REVIEWS3007.
[Genome Biol. 2001]EMBO Rep. 2005 Dec; 6(12):1137-42.
[EMBO Rep. 2005]J Biol Chem. 1993 Feb 25; 268(6):4391-8.
[J Biol Chem. 1993]J Biol Chem. 1992 Feb 15; 267(5):3423-8.
[J Biol Chem. 1992]Trends Cell Biol. 2002 Feb; 12(2):65-71.
[Trends Cell Biol. 2002]Mol Cell Biol. 2002 Jun; 22(11):3599-609.
[Mol Cell Biol. 2002]J Biol Chem. 2003 Sep 19; 278(38):36754-62.
[J Biol Chem. 2003]Nature. 2003 Apr 10; 422(6932):629-33.
[Nature. 2003]Proc Natl Acad Sci U S A. 2002 Oct 1; 99(20):12835-40.
[Proc Natl Acad Sci U S A. 2002]Curr Biol. 1997 Jul 1; 7(7):479-87.
[Curr Biol. 1997]Dev Cell. 2005 Dec; 9(6):791-804.
[Dev Cell. 2005]J Biol Chem. 2000 Mar 17; 275(11):7854-61.
[J Biol Chem. 2000]Biochem Biophys Res Commun. 2006 Feb 17; 340(3):967-75.
[Biochem Biophys Res Commun. 2006]Nat Cell Biol. 2005 Jun; 7(6):559-69.
[Nat Cell Biol. 2005]Proc Natl Acad Sci U S A. 2002 Oct 1; 99(20):12835-40.
[Proc Natl Acad Sci U S A. 2002]Proc Natl Acad Sci U S A. 2002 Oct 1; 99(20):12835-40.
[Proc Natl Acad Sci U S A. 2002]Trends Cell Biol. 2006 Jan; 16(1):27-35.
[Trends Cell Biol. 2006]Cell. 2004 Sep 3; 118(5):607-17.
[Cell. 2004]Genome Biol. 2001; 2(5):REVIEWS3007.
[Genome Biol. 2001]Nature. 1998 Jul 30; 394(6692):494-8.
[Nature. 1998]Cell. 1995 Nov 3; 83(3):423-32.
[Cell. 1995]Proc Natl Acad Sci U S A. 2002 Oct 1; 99(20):12835-40.
[Proc Natl Acad Sci U S A. 2002]J Cell Biol. 1994 Mar; 124(5):705-15.
[J Cell Biol. 1994]J Cell Biol. 1993 Jun; 121(6):1221-32.
[J Cell Biol. 1993]J Cell Biol. 1992 Jun; 117(6):1181-96.
[J Cell Biol. 1992]Proc Natl Acad Sci U S A. 1991 Sep 1; 88(17):7815-9.
[Proc Natl Acad Sci U S A. 1991]J Biol Chem. 2001 Dec 28; 276(52):49331-6.
[J Biol Chem. 2001]Nat Cell Biol. 2001 Apr; 3(4):368-75.
[Nat Cell Biol. 2001]J Cell Biol. 2001 Aug 20; 154(4):829-40.
[J Cell Biol. 2001]Mol Biochem Parasitol. 2000 Feb 25; 106(1):21-35.
[Mol Biochem Parasitol. 2000]J Neurosci Res. 2001 Dec 15; 66(6):1149-60.
[J Neurosci Res. 2001]Mol Cell Biol. 2001 Jul; 21(14):4785-806.
[Mol Cell Biol. 2001]Proc Natl Acad Sci U S A. 2002 Oct 1; 99(20):12835-40.
[Proc Natl Acad Sci U S A. 2002]Nat Cell Biol. 2005 Jun; 7(6):559-69.
[Nat Cell Biol. 2005]Trends Cell Biol. 2006 Jan; 16(1):27-35.
[Trends Cell Biol. 2006]Cell. 2004 Sep 3; 118(5):607-17.
[Cell. 2004]Genome Biol. 2001; 2(5):REVIEWS3007.
[Genome Biol. 2001]Cell. 1997 Sep 19; 90(6):1149-59.
[Cell. 1997]Dev Cell. 2001 Jul; 1(1):73-82.
[Dev Cell. 2001]Mol Biochem Parasitol. 2000 Feb 25; 106(1):21-35.
[Mol Biochem Parasitol. 2000]J Neurosci Res. 2001 Dec 15; 66(6):1149-60.
[J Neurosci Res. 2001]Curr Biol. 1998 Jul 16; 8(15):881-4.
[Curr Biol. 1998]J Biol Chem. 1999 Oct 8; 274(41):28857-60.
[J Biol Chem. 1999]J Cell Biol. 1998 Nov 16; 143(4):973-90.
[J Cell Biol. 1998]J Cell Biol. 1996 Aug; 134(3):625-35.
[J Cell Biol. 1996]Mol Biol Cell. 2003 Mar; 14(3):973-86.
[Mol Biol Cell. 2003]EMBO J. 2004 May 19; 23(10):2059-70.
[EMBO J. 2004]Mol Biol Cell. 2002 Jul; 13(7):2421-35.
[Mol Biol Cell. 2002]Nat Rev Mol Cell Biol. 2002 Apr; 3(4):267-77.
[Nat Rev Mol Cell Biol. 2002]Dev Cell. 2002 Mar; 2(3):283-94.
[Dev Cell. 2002]Am J Physiol Renal Physiol. 2003 May; 284(5):F893-901.
[Am J Physiol Renal Physiol. 2003]Nature. 2003 Oct 16; 425(6959):727-33.
[Nature. 2003]Nature. 2003 Apr 10; 422(6932):629-33.
[Nature. 2003]Mol Biol Cell. 2006 May; 17(5):2303-11.
[Mol Biol Cell. 2006]Eur J Biochem. 2002 Jan; 269(1):259-71.
[Eur J Biochem. 2002]Mol Biochem Parasitol. 2000 Feb 25; 106(1):21-35.
[Mol Biochem Parasitol. 2000]Proc Natl Acad Sci U S A. 2002 Oct 1; 99(20):12835-40.
[Proc Natl Acad Sci U S A. 2002]Proc Natl Acad Sci U S A. 2002 Oct 1; 99(20):12835-40.
[Proc Natl Acad Sci U S A. 2002]Nature. 2000 Sep 14; 407(6801):202-7.
[Nature. 2000]Mol Biol Cell. 2006 May; 17(5):2303-11.
[Mol Biol Cell. 2006]Gene. 1988 Jul 15; 67(1):31-40.
[Gene. 1988]Proc Natl Acad Sci U S A. 2002 Oct 1; 99(20):12835-40.
[Proc Natl Acad Sci U S A. 2002]Mol Biol Cell. 2006 May; 17(5):2303-11.
[Mol Biol Cell. 2006]Mol Cell Biol. 2001 Jul; 21(14):4785-806.
[Mol Cell Biol. 2001]